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Background:  Although previous reports showed that circulating oxidized low-density lipoprotein (oxLDL) levels correlated with the severity 
of coronary artery disease (CAD), the clinical utility of oxLDL as a biomarker is not established yet. We have recently developed a new 
system that can quantify the accurate expression of leukocyte mRNA by real time polymerase chain reaction using whole blood. In this 
study, we aimed to develop a novel blood test for risk stratification in CAD by the immune response against oxLDL.
methods:  A total of 43 patients with prior history of percutaneous coronary intervention were enrolled. The blood samples were collected 
before follow-up coronary angiography. Heparinized whole blood was stimulated with 0.4 mg/ml of oxLDL or a control for 4 hours. Then, the 
changes of various mRNA expression in leukocyte were quantified by our new system.
results:  Coronary angiography revealed that 26 patients had progressed lesions required repeat revascularization. OxLDL stimulation 
increased membrane type 1 metalloproteinase (MT1-MMP) mRNA expression in leukocytes from patients with progressed lesions. When 
cutoff value of logarithm of MT1-MMP expression was set at 0.3 determined by receiver operating characteristic (ROC) curve, high MT1-
MMP expression was an independently significant predictor of progressed lesions assessed by logistic regression analysis after adjustment 
for age and gender (Odds Ratio: 7.9, 95% CI: 1.6-39.3, p=0.01). The high MT1-MMP expression also had larger area under the ROC 
curve (AUC) for predicting progressed lesions compared to known risk factors for CAD such as high-sensitive CRP (hsCRP) and/or LDL 
cholesterol (LDL-C) (AUC: MT1-MMP=0.83, hsCRP=0.73, LDL-C=0.78, hsCRP+LDL-C=0.79). Moreover, ROC analysis showed that the 
high MT1-MMP expression significantly improved the prediction of progressed lesions when added to hsCRP plus LDL-C (AUC: MT1-
MMP+hsCRP+LDL-C=0.94, hsCRP+LDL-C=0.79, p=0.04).
Conclusion:  OxLDL-induced high MT1-MMP expression in leukocyte was significantly associated with progressed lesions. This study 
suggests that MT1-MMP induction by oxLDL stimulation could be a novel blood test for risk stratification in CAD.
